Dolby Laboratories, Inc. (DLB) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Dolby Laboratories, Inc. (DLB) stock forecast summary
On Oct. 13, 2026, DLB is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
Dolby Laboratories, Inc. is a mid-cap company with a market capitalization of $5.47B. It ranks number 2 by market capitalization among the 10 Patent Owners & Lessors issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for DLB is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, DLB included.
Follow DLB freeDLB price chart and AI forecast
How DLB ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Dolby Laboratories, Inc. (DLB) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Patent Owners & Lessors peers listed below that report each metric.
Valuation & Market
| Metric | DLB | Rank |
|---|---|---|
| Market Cap | $5.47B | 2/10 |
| P/E Ratio | 24.17x | – |
| P/B Ratio | 2.12x | 6/9 |
| Dividend Yield | 2.46% | – |
| EPS | $2.49 | – |
| Book Value/Share | $27.58 | – |
| Revenue/Share | $14.46 | – |
| FCF/Share | $4.19 | – |
Profitability & Margins
| Metric | DLB | Rank |
|---|---|---|
| ROE | 8.8% | 3/10 |
| ROA | 7.2% | 3/10 |
| ROIC | 8.7% | 5/12 |
| Gross Margin | 87.6% | 1/6 |
| Operating Margin | 17.6% | 2/10 |
| Net Margin | 16.7% | 2/9 |
| EBT Margin | 20.4% | 2/10 |
| Tax Rate | 17.6% | – |
Financial Health
| Metric | DLB | Rank |
|---|---|---|
| Current Ratio | 3.19x | 5/12 |
| Quick Ratio | 3.11x | – |
| D/E Ratio | 0.22x | 9/11 |
| Financial Leverage | 1.22x | 9/11 |
| Interest Coverage | 1.9x | 4/10 |
| Working Capital | $910M | 1/12 |
Cash Flow
| Metric | DLB | Rank |
|---|---|---|
| Operating Cash Flow | $438M | 2/12 |
| Free Cash Flow | $393M | 2/5 |
| Capital Spending | -$45M | 5/5 |
| OCF Growth YoY | -6.0% | 5/6 |
| FCF Growth YoY | -10.4% | – |
| FCF/Sales | 29.0% | – |
| CapEx/Sales | 3.3% | – |
Operational Efficiency
| Metric | DLB | Rank |
|---|---|---|
| Asset Turnover | 0.43x | 3/8 |
| Receivables Turnover | 4.8x | 3/7 |
| Inventory Turnover | 5.5x | – |
| Fixed Assets Turnover | 3.0x | 7/8 |
| Days Sales Outstanding | 77 days | 5/8 |
| Days Inventory | 67 days | – |
| Payables Period | 27 days | 6/6 |
| Cash Conversion Cycle | 117 days | – |
Income Statement
| Metric | DLB | Rank |
|---|---|---|
| Total Revenue | $1.35B | 1/8 |
| Operating Income | $239M | 2/12 |
| Net Income | $226M | 2/10 |
| R&D Expense | $266M | – |
| SG&A Expense | $921M | 1/8 |
| Cost of Goods Sold | $168M | 3/7 |
Dividend & Shareholder Information
| Metric | DLB | Rank |
|---|---|---|
| Dividends Per Share | $1.43 | – |
| Payout Ratio | 57.4% | – |
| Shares Outstanding | 94M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.33B | 42.0% of assets |
| Cash & Short-term Investments | $669M | 21.2% of assets |
| Accounts Receivable | $285M | 9.0% of assets |
| Inventory | $31M | 1.0% of assets |
| Total Liabilities | $564M | 17.9% of assets |
| Short-term Debt | $404M | 12.8% of assets |
DLB quarterly financials and insider trading
Dolby Laboratories, Inc. (DLB) industry peers
Companies classified under the same SEC industry code as Dolby Laboratories, Inc. (Patent Owners & Lessors): 12 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| DLB Dolby Laboratories, Inc. | ▶ | $5.47B |
| IDCC Interdigital, Inc. | ▶ | $8.59B |
| APPS Digital Turbine, Inc. | ▲ | $1.25B |
| ACTG Acacia Research Corp | ▶ | $429M |
| JYNT Joint Corp | ▲ | $99M |
| VHC Virnetx Holding Corp | ▲ | $46M |
| NTIP Network-1 Technologies, Inc. | ▶ | $35M |
| REFR Research Frontiers Inc | ▶ | $21M |
| XELB Xcel Brands, Inc. | ▲ | $3M |
| AMOD Alpha Modus Holdings, Inc. | ▼ | $2M |
| AERA Ai Era Corp. | ▶ | N/A |
| RMCO Royalty Management Holding Corp | ▶ | N/A |
Where DLB sits on the market map
Dolby Laboratories, Inc. (DLB) stock news
Loading...
Dolby Laboratories, Inc. (DLB) stock forecast FAQ
What is the Dolby Laboratories, Inc. (DLB) stock forecast?
On Oct. 13, 2026, DLB is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
How accurate are Dolby Laboratories, Inc. stock predictions?
A per-ticker accuracy statistic for DLB is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Dolby Laboratories, Inc. forecasts updated?
Dolby Laboratories, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Dolby Laboratories, Inc.'s industry peers?
12 issuers in our coverage, DLB included, share the SEC industry code Patent Owners & Lessors. The largest are: Interdigital, Inc. (IDCC), Digital Turbine, Inc. (APPS), Acacia Research Corp (ACTG), Joint Corp (JYNT), Virnetx Holding Corp (VHC), Network-1 Technologies, Inc. (NTIP).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.